Eight abstracts cover FLT3 mutation-positive AML, patient treatment preferences and utilization in hard-to-treat blood cancer

TOKYO, June 8, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the European Hematology Association (EHA) virtual congress, taking place June 9-17. 

Eight Astellas-sponsored abstracts focused on patients with AML are being presented, comprising two oral presentations, four posters and two online-only abstract publications. 

“We’re pleased to present new investigational research at EHA 2021 that examines how patients and healthcare providers value different treatment approaches in AML,” said Erhan Berrak, M.D., Vice President of Medical Affairs, Oncology, Astellas. “For example, one oral presentation sheds light on patients’ preferences for treatment, which may help to inform decisions of healthcare professionals when considering a plan for treatment after hematopoietic stem cell transplantation.” 

“Clinical trial results to be presented reflect our deep commitment to AML research, where we are investigating gilteritinib as monotherapy or in combination with other treatments, and across the range of patients with FLT3 mutation-positive AML, including patients whose AML is newly diagnosed or relapsed or refractory,” said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head, Astellas. 

Oral Presentations
Oral presentations are available online from Friday, June 11 at 9 a.m. CEST, when all prerecorded presentations will be published on the virtual congress platform.

Title: Patient and Physician Preferences for Post–Hematopoietic Stem Cell Transplantation
Maintenance Treatment of Acute Myeloid Leukemia (Abstract S313)

•    Presenting author: Manasee V. Shah, Astellas Pharma Inc., Northbrook, Ill., USA

Title: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study (Supported by AbbVie, Astellas and Genentech) (Abstract S135)
•    Presenting author: Jessica K. Altman, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill., USA

E-Poster Presentations
E-poster presentations are available from Friday, June 11 at 9 a.m. CEST, when the e-posters are published on the virtual congress platform.

Title: Follow-up of Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid
Leukemia in the Phase 3 ADMIRAL Trial (Abstract EP438)

•    Presenting author: Mark J. Levis, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Md., USA

Title: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib (Abstract EP448)

•    Presenting author: Alexander E. Perl, Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, Pa., USA

Title: Outcomes in Gilteritinib-Treated FLT3-Mutated R/R AML Patients Who Underwent
Transplantation (Abstract EP441)

•    Presenting author: Alexander E. Perl, Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, Pa., USA

Title: A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results Update (Abstract EP437)
•    Presenting author: Keith W. Pratz, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Md., USA

Online-only abstract publications
Online-only abstracts are available via the virtual congress platform.

Title: Retrospective Assessment of Treatment Patterns and Resource Utilization for Patients Newly Diagnosed with Acute Myeloid Leukemia in Canada, UK, France, Germany, Italy, and Spain (Abstract PB1390)

Title: Frequency of FLT3-ITD and FLT3-TKD Mutations in Patients with Acute Myeloid
Leukemia: A Systematic Literature Review and Meta-Analysis (Abstract PB1405)

The EHA 2021 virtual congress abstracts are available in the EHA Library

 

Click below for a copy of the full press release

Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)